Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
This paper reviews the factors governing the rate of iron loading and iron toxicity in the thalassaemia syndromes and sickle cell disease. It outlines the main determinants of iron mobilization by the iron-chelating drug, desferrioxamine, together with the effects of this drug in clinical practice.
D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D001205:Ascorbic Acid / Q000627:therapeutic use; D003676:Deferoxamine / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005544:Forecasting; D006801:Humans; D007501:Iron / Q000097:blood*; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D012805:Sickle Cell Trait / Q000188:drug therapy*; D013789:Thalassemia / Q000188:drug therapy*
D007502:Iron Chelating Agents; D007501:Iron; D003676:Deferoxamine; D001205:Ascorbic Acid